Fenofibrate, a PPAR-α agonist, is commonly used for hyperlipidemia treatment and has demonstrated potential anticancer effects, as it influences apoptosis, cell-cycle arrest, invasion, and migration in various cancer cell lines, including those of breast, liver, glioma, prostate, pancreas, and lung cancer (Lian et al., 2018). Here, PPARA is linked to glioma.